Nova Eye Medical (EYE) Discussion, page-3121

Again that's speculation assuming that the additional expenditure is not being met with additional growth. We should find out in early July whether such concerns are warranted, but they have a good track record of being pretty good at avoiding burning cash too fast. The launch of this device obviously required a lot more cash than usual, I would expect now that this device has been in the market for around a year that they'd now be generating revenues at a fast enough growth rate to offset additional expenditures and that the net loss would be improving towards a net profit (if not that would probably be a good reason for concern though). We actually saw this last year, with a steadily improving bottom line (albeit not enough to avoid needing to raise).

For this reason though the bottom line performance will be most important to me. They're targeting cash flow positive in FY25 so I'd really be expecting the bottom line to improve quite a bit, or your fear may be justified. Let's see what happens.